Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Accumulated Expenses (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Accumulated Expenses for 13 consecutive years, with $260.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 108.82% to $260.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $260.4 million, a 108.82% increase, with the full-year FY2025 number at $260.4 million, up 108.82% from a year prior.
  • Accumulated Expenses was $260.4 million for Q4 2025 at Madrigal Pharmaceuticals, down from $345.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $345.4 million in Q3 2025 to a low of $44.1 million in Q1 2021.
  • A 5-year average of $110.0 million and a median of $87.8 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: fell 1.62% in 2023, then soared 163.64% in 2025.
  • Madrigal Pharmaceuticals' Accumulated Expenses stood at $55.0 million in 2021, then soared by 66.15% to $91.5 million in 2022, then fell by 1.62% to $90.0 million in 2023, then skyrocketed by 38.58% to $124.7 million in 2024, then soared by 108.82% to $260.4 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Accumulated Expenses are $260.4 million (Q4 2025), $345.4 million (Q3 2025), and $157.5 million (Q2 2025).